Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.


CSE:SONA - Post by User

Comment by shoosh22on Aug 27, 2020 7:47am
148 Views
Post# 31459170

RE:Symptomatic vs Asymptomatic

RE:Symptomatic vs AsymptomaticYou know in NR they have to be very careful what they say until they have the FDA approval.  The whole point of the SONA TEST and has been right from the beginning is that it can detect the virus at very low levels, sometimes within the first 24hrs of infection.  I think you should do a deeper dive on SONA to see exactly what it is they have.. sonanano.com  There website if full of data and demonstartions of how their tech works.  Abbott only tested on Symptomatic.  It is true the last PR when stating Field Results it was limited to end numbers and it is hard to decifer if in fact Sona tested on Asymptomatic..which if they did well Sona's test blows the others out of the water.  I would rather folks find out they are positive on day 1 of the infection and not have to wait for a full week after symptoms start... That two weeks walking around infecting people.  You choose.. What would you want.. seriously...There are much smarter people over on CEO who understand this much better than I...But my faith is in Sona.. 

ote=MikeyH]With Abbott's bombshell announcement yesterday, we are now down to a very simple situation. Can the Sona test really detect the virus pre (or very early) symptoms or not? If the answer is 'yes', then Sona is firmly in the game still. If the answer is 'no', then there is trouble ahead. And here's why:

In the last NR Rowles stated:

"Rapid, point-of-care, antigen tests can make a significant contribution to reducing the spread of COVID-19 by detecting the presence of the virus, potentially before the onset of symptoms"

So, this seems to be a generic statement on Antigen tests rather than on Sona's test. Can Sona actually achieve this? There has been lots of speculation that it can here, on CEO and on twitter but we need to see the proof. Where is the data that suggests this? Someone on Twitter tried to suggest that because there was 60 negatives, then the study was focused on asymptomatic individuals but that is pure speculation which seems to now have been accepted as fact by some investors. This is dangerous.

Abbott's test comes with very clear claims regarding when it is sensitive and when it isn't. Sona needs to do the same, and fast. GLTA
[/quote]

<< Previous
Bullboard Posts
Next >>